Triage Considerations for Patients Referred for Structural Heart Disease Intervention During the COVID-19 Pandemic
Pinak Shah, Saif Anwaruddin(Harvard University), Alistair Phillips(American College of Cardiology), Wayne Batchelor(Inova Health System), Molly Szerlip(Heart Hospital Baylor Plano), Laura Davidson(American College of Cardiology), Neal S. Kleiman(Houston Methodist), Dee Dee Wang(University of London), Frederick G.P. Welt(Harvard University), Janet Wyman(American College of Cardiology), Sabeeda Kadavath(American College of Cardiology), Matthew W. Sherwood(Inova Fairfax Hospital), Michael N. Young(Dartmouth–Hitchcock Medical Center), David A. Fullerton(University of Denver), James Hermiller(St. Vincent Hospital), Ehtisham Mahmud(University of California San Diego)
Cited by 102
Related Papers
Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association
|Circulation|2017|3.7k
The N-terminal Pro-BNP Investigation of Dyspnea in the Emergency department (PRIDE) study
|The American Journal of Cardiology|2005|1.2k
Adv. Drug Delivery Rev.
|Advanced Drug Delivery Reviews|1997|863
Intravenous Platelet Blockade with Cangrelor during PCI
|New England Journal of Medicine|2009|643
Inflammation and Restenosis in the Stent Era
|Arteriosclerosis Thrombosis and Vascular Biology|2002|622